Shots:

• Novartis out-licensed worldwide rights for its three drug candidates- including LYS228 & IID572 targeting carbapenem-resistant enterobacteriaceae (CRE) and MAK181 targeting Pseudomonas infections. Boston to pay an upfront- milestone and royalty payments on sales to Novartis
• Additionally- Novartis to get an equity stakes in two new companies formed together with Boston for development and commercialization of these programs
•  LYS228 is a monobactum currently evaluated in P-II- to treat Intra-abdominal infections. IID572 is a novel beta-lactamase inhibitor used to expand their use against difficult-to-treat infections caused by CRE. MAK181 is an oral- novel LpxC inhibitor for Pseudomonas infections

Ref: Novartis | Image: Boston Pharmaceuticals